727 related articles for article (PubMed ID: 17180470)
1. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
4. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of DNA vaccine potency by sandwiching antigen-coding gene between secondary lymphoid tissue chemokine (SLC) and IgG Fc fragment genes.
Liu R; Zhou C; Wang D; Ma W; Lin C; Wang Y; Liang X; Li J; Guo S; Wang Y; Zhang Y; Zhang S
Cancer Biol Ther; 2006 Apr; 5(4):427-34. PubMed ID: 16575207
[TBL] [Abstract][Full Text] [Related]
8. Novel chemotactic-antigen DNA vaccine against cancer.
Zhang S; Zhang Y
Future Oncol; 2008 Apr; 4(2):299-303. PubMed ID: 18407741
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
10. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
[TBL] [Abstract][Full Text] [Related]
11. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
12. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
14. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
15. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
16. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
17. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
18. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
